Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005-2014
- PMID: 30456446
- PMCID: PMC6380970
- DOI: 10.1007/s13555-018-0268-8
Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005-2014
Abstract
Introduction: The aim of this study is to describe the disease burden and costs of herpes zoster (HZ) in the general adult Japanese population or patients with immunocompromised (IC) conditions or chronic disorders.
Methods: A retrospective cohort study of individuals aged 18-74 years was conducted using January 2005 to December 2014 records from the Japan Medical Data Center claims database. Twenty-eight IC conditions and chronic disorders were defined by diagnosis codes and/or procedures/treatments. HZ and its related complications were identified. Incidence rates (IR), frequency of HZ-related complications, healthcare resource utilization (HRU), and direct medical costs were estimated. HRU and costs were estimated on a subcohort of HZ cases occurring April 2012-January 2014.
Results: The overall IR of HZ in the total cohort of 2,778,476 adults was 4.92/1000 person-years (PY) [95% confidence interval (CI): 4.86-4.98] and increased with age. The IR in the IC cohort (51,818 subjects) was 8.87/1000 PY (95% CI: 8.29-9.48), ranging from 5.55/1000 PY (95% CI: 4.26-7.09) in psoriasis to 151.68/1000 PY (95% CI: 111.45-201.71) in hematopoietic stem cell transplant recipients; most IRs were in the range 6-10/1000 PY. The IRs in individuals with chronic disorders were also relatively high, in the range 5.40-12.90/1000 PY. The frequency of postherpetic neuralgia was 4.01% (95% CI: 3.72-4.33) in the total cohort and 11.73% (95% CI: 9.01-14.93) in the IC cohort. The mean [standard deviation (SD)] number of outpatient visits was 3.4 (4.9) and 5.0 (5.7), respectively, and the proportion of HZ patients hospitalized was 2.20% and 6.70%, respectively. The mean (SD) direct medical cost per HZ episode was ¥34,664 (¥54,433) and ¥55,201 (¥92,642) in the total and IC cohort, respectively.
Conclusions: The elevated burden of HZ in Japanese individuals harboring IC conditions and chronic disorders documented in our study underlines the need for prevention of HZ in people with these conditions.
Funding: GlaxoSmithKline Biologicals SA.
Keywords: Claims database; Healthcare resource utilization; Herpes zoster; Immunocompromised; Japan; Medical cost; Postherpetic neuralgia.
Figures

Similar articles
-
Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012.BMJ Open. 2018 Jun 7;8(6):e020528. doi: 10.1136/bmjopen-2017-020528. BMJ Open. 2018. PMID: 29880565 Free PMC article.
-
Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis.BMJ Open. 2019 Aug 27;9(8):e023502. doi: 10.1136/bmjopen-2018-023502. BMJ Open. 2019. PMID: 31462457 Free PMC article.
-
Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: Results from a claims database cohort study, from 2005 to 2014.J Dermatol. 2020 Mar;47(3):236-244. doi: 10.1111/1346-8138.15214. Epub 2020 Jan 17. J Dermatol. 2020. PMID: 31953880
-
Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.Aging Clin Exp Res. 2009 Jun;21(3):236-43. doi: 10.1007/BF03324909. Aging Clin Exp Res. 2009. PMID: 19571648 Review.
-
Vaccination: a new option to reduce the burden of herpes zoster.Expert Rev Vaccines. 2010 Mar;9(3 Suppl):31-5. doi: 10.1586/erv.10.32. Expert Rev Vaccines. 2010. PMID: 20192716 Review.
Cited by
-
Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009-2014.BMC Infect Dis. 2020 Nov 30;20(1):905. doi: 10.1186/s12879-020-05648-6. BMC Infect Dis. 2020. PMID: 33256624 Free PMC article.
-
Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis.Eur Respir J. 2024 Aug 8;64(2):2400462. doi: 10.1183/13993003.00462-2024. Print 2024 Aug. Eur Respir J. 2024. PMID: 38901886 Free PMC article.
-
Effectiveness of Live Attenuated Varicella-Zoster Vaccine in Adults Older than 50 Years in Japan: A Retrospective Cohort Study.Vaccines (Basel). 2023 Jan 25;11(2):259. doi: 10.3390/vaccines11020259. Vaccines (Basel). 2023. PMID: 36851138 Free PMC article.
-
Clinical, Laboratory, and Imaging Characteristics of Tropheryma Whipplei Detection in Bronchoalveolar Lavage Fluid Using Next-Generation Sequencing: A Case-Control Study.Infect Drug Resist. 2024 Jul 17;17:3101-3112. doi: 10.2147/IDR.S470084. eCollection 2024. Infect Drug Resist. 2024. PMID: 39050831 Free PMC article.
-
Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns.Infection. 2024 Jun;52(3):1009-1026. doi: 10.1007/s15010-023-02156-y. Epub 2024 Jan 18. Infection. 2024. PMID: 38236326 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Miscellaneous